Allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis arises when the immune system mounts an exaggerated response to persistent airway exposure to Aspergillus species, most notably in individuals living with asthma or cystic fibrosis. Instead of a straightforward infection, it manifests as an inflammatory and immunologic condition where hypersensitivity drives airway obstruction, recurrent flare-ups, and, if not controlled, gradual structural damage to the lungs. Clinicians often face challenges in timely identification, as its presentation overlaps with common respiratory conditions, leading to underdiagnosis and delays in care. Modern diagnostic strategies increasingly rely on a combination of advanced imaging, immunoglobulin measurements, and sputum analysis to differentiate it from other chronic pulmonary disorders.

Management traditionally relies on corticosteroids to limit inflammation, with antifungal medications introduced to decrease fungal burden and minimize reliance on long-term steroids. More recently, biologic therapies directed at immune pathways have been explored, particularly for difficult-to-treat cases, showing encouraging results in reducing exacerbations and dependence on systemic steroids. Ongoing monitoring with lung function testing and imaging is essential to track disease progression and treatment efficacy. The broader approach to allergic bronchopulmonary aspergillosis incorporates not only pharmacologic interventions but also patient awareness, long-term follow-up, and multidisciplinary collaboration. As research continues to clarify genetic susceptibility and host–fungus interactions, future therapies are likely to become more personalized, aiming to preserve lung integrity and improve long-term quality of life.